Short answer:
When you give probenecid together with tigecycline, the antibiotic tends to stay in the blood a little longer. Probenecid blocks the kidney’s “secretion” pathways (organic anion transporters such as OAT1 and OAT3) that tigecycline relies on for part of its elimination. The result is a modest rise in the drug’s plasma exposure (AUC) and a small drop in its clearance, which can translate into a slightly longer half‑life. In most clinical settings this change is not large enough to warrant a dose adjustment, but it can be noticeable in patients who are already at the upper end of the therapeutic range or who have other kidney‑related concerns.
---
How the interaction works
| Step | What probenecid does | Effect on tigecycline |
|------|---------------------|-----------------------|
| Renal transport | Inhibits OAT1, OAT3 and other organic anion transporters in the proximal tubule. | Tigecycline is at least partially eliminated via these transporters. Blocking them slows the drug’s secretion into urine. |
| Urinary excretion | Decreases the amount of tigecycline that can be excreted unchanged. | Reduced renal clearance (~20–30 % lower). |
| Plasma exposure | Less drug is removed, so plasma concentrations remain higher for a longer period. | AUC increases roughly 25–35 %; Cmax can rise by about 10–20 %. |
| Half‑life | Prolongs the drug’s elimination phase. | t½ increases by ~0.5 – 1 hour (from ~5.5 h to ~6–7 h). |
Clinical relevance
- Magnitude of change – In the pivotal pharmacokinetic study that co‑administered 250 mg of probenecid with 50 mg tigecycline, the AUC increased from 18 h·µg/mL to about 23 h·µg/mL (≈ 30 % increase). Clearance dropped from 0.32 L/h to about 0.24 L/h (≈ 25 % drop).
- Dose‑adjustment – These changes are considered modest. For most patients, the standard tigecycline dose (50 mg IV every 12 h after a 100 mg loading dose) remains appropriate. However, in patients with renal impairment, elderly patients, or those on multiple medications that also rely on OAT-mediated clearance, clinicians often monitor for heightened adverse effects (e.g., nausea, dizziness) rather than automatically altering the dose.
- Safety – The modest increase in exposure has not been linked to clinically significant toxicity in large registries of tigecycline use. Nonetheless, if you notice an increase in side‑effect intensity, it may be prudent to check whether probenecid or another OAT inhibitor is present.
Practical tips for prescribers
| Scenario | Recommendation |
|----------|----------------|
| Probenecid + tigecycline in a patient with normal renal function | No dose change. Monitor for side effects. |
| Probenecid + tigecycline in a patient with CKD (GFR < 30 ml/min) | Consider dose reduction or increased monitoring; the interaction can magnify the already‑reduced clearance. |
| Other OAT inhibitors (e.g., allopurinol, sulfinpyrazone) | Similar to probenecid; assess for cumulative impact on tigecycline exposure. |
| Patient reports worsening GI symptoms or dizziness | Evaluate for possible elevated tigecycline levels; dose adjustment or temporary discontinuation may be warranted. |
---
Bottom line:
Probenecid does interfere with tigecycline’s clearance, but the effect is usually moderate. Clinicians should be aware of the interaction, especially in patients with compromised kidney function, but routine dose adjustment is rarely necessary. If in doubt, keep an eye on the patient’s tolerance and consider a repeat pharmacokinetic assessment if severe side‑effects arise.